Jonathan Leff
InvestorExecutive Partner, Private Equity at Sofinnova Ventures · Board director at Axonis Therapeutics · Board director at Adaptive Phage Therapeutics
Menlo Park, California
Writes $100K – $5M checks · typically $1.5M
About
Jonathan Leff is a physician with over 25 years of clinical development experience in the biotechnology and pharmaceutical industry, advising companies on drug development from target identification through market approval. Before joining Sofinnova in 2020, he was SVP and Chief Medical Officer of Ascendis Pharma, EVP of Research and Development at InterMune (where he led development and US approval of Esbriet for idiopathic pulmonary fibrosis), and held CMO roles at KaloBios Pharmaceuticals and Halozyme Therapeutics, plus positions at Roche, Amgen, and Merck. He holds a B.A. in Chemistry and an M.D. from the University of Pennsylvania, and completed training in Internal Medicine and Pulmonary and Critical Care Medicine at the University of Colorado, Denver.
Contact· self-published, not guessed
Invests in
Biotech
Board director at Axonis Therapeutics
Intro paths
→
In turn, Jonathan can intro founders to Axonis Therapeutics's investors below.
Axonis Therapeutics's investors · 15
BoxOne VenturesMontréal · $500K checks · since 2024Civilization Ventures Management, LlcTiburon · $1M – $10M checks · since 2024Creative Destruction Lab (CDL)Toronto · $50K – $250K checks · since 2024Hatteras Venture PartnersResearch Triangle · $500K – $4M checks · since 2024Iaso VenturesCambridge · since 2024Lumira VenturesToronto · $1M – $10M checks · since 2024MRL Ventures FundCambridge · $25M checksNational Institutes of Health (NIH)since 2020Pathway BioventuresChicago · since 2024SCI VenturesLondon · since 2024Sofinnova VenturesMenlo Park · $100K – $15M checks · since 2024Solasta VenturesBoston · since 2024Tachyon VenturesLos Angeles · since 2024venBio Global StrategicSan Francisco · since 2024venBio PartnersSan Francisco · since 2024
Co-founders at Axonis Therapeutics
SH
Shane HegartyExecutive Officer
SV
Shane V. HegartyChief Scientific Officer & Co-Founder
Board director at Adaptive Phage Therapeutics
Intro paths
→
In turn, Jonathan can intro founders to Adaptive Phage Therapeutics's investors below.
Adaptive Phage Therapeutics's investors · 2
Co-founders at Adaptive Phage Therapeutics
GL
Gregory L. MerrilExecutive Officer, Director, Promoter
CR
Carl R. MerrilExecutive Officer, Director
Experience
- Axonis TherapeuticsBoard Membercurrent2024 — presentBoston, Massachusetts, United States
- Sofinnova InvestmentsExecutive Partnercurrent2020 — presentMenlo Park
- Avalyn PharmaBoard Member2017 — 2026Greater Boston Area
- NorthSea TherapeuticsBoard Member2022 — 2026The Netherlands
- Aerovate TherapeuticsBoard Member2020 — 2021
- Ascendis Pharma A/SSenior Vice President and Chief Medical Officer2016 — 2019Palo Alto, CA
- InterMuneExecutive Vice President, Research and Development2012 — 2015Brisbane, CA
- KaloBios IncChief Medical Officer2011 — 2012San Francisco Bay Area
- Halozyme Therapeutics, Inc.Vice President and Chief Medical Officer2009 — 2010
- RocheVice President, Global Head Inflammation Clinical Development2007 — 2009
- RocheVice President2007 — 2009Palo Alto, California
- AmgenVice President - North America Medical Affairs2002 — 2007
- MerckSenior Director1994 — 2002
- University of Colorado Anschutz Medical CampusAssistant Professor1990 — 1994Denver, Colorado
Skills & more
Clinical Development96Clinical Trials77Biotechnology54Oncology50Clinical Research32Drug Development25Life Sciences19FDA18Biopharmaceuticals13Rheumatology8Immunology6Pharmaceutics6
+12 more
DermatologyDrug DiscoveryInfectious DiseasesRegulatory AffairsCancerMedicineLifesciencesInternal MedicinePharmaceutical IndustryStrategyAnalysisLeadership- Diplomat, Critical Care Medicine — American Board of Internal Medicine
- Diplomat, American Board of Internal Medicine, Pulmonary Disease — American Board of Internal Medicine
- Diplomat, American Board of Internal Medicine — American Board of Internal Medicine
- License to Practice Medicine — State of California
From Jonathan's professional profile.
Deals · 3
Genoa PharmaceuticalsBoard seat
via Sofinnova Ventures · filed Oct 2023 · $189.2M raise
Adaptive Phage TherapeuticsBoard seat
via Sofinnova Ventures · filed Jun 2023 · $30M raise
Aerovate Therapeutics, Inc.Board seat
via Sofinnova Ventures · filed Aug 2020 · $75.8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
AxonisExpeditionNorthSea
Sources: SEC Form D filings · the firm's website.
Colleagues at Sofinnova Ventures
Alex Chan
Controller, Private Equity at Sofinnova Ventures
Alex Dulnev
IT Manager at Sofinnova Ventures
Amanda Phillips
Executive Assistant at Sofinnova Ventures
Anastasia Voevodin
Analyst, Public Equity at Sofinnova Ventures
Aneal Tenjarla
Partner, Associate Portfolio Manager, Public Equity at Sofinnova Ventures
Calvin Sternick
Analyst, Public Equity at Sofinnova Ventures
Chris Carpenter
Executive Partner, Private Equity at Sofinnova Ventures
David Kabakoff
Executive Partner, Private Equity at Sofinnova Ventures
Frequently asked questions
- Who is Jonathan Leff?
- Jonathan Leff is a physician with over 25 years of clinical development experience in the biotechnology and pharmaceutical industry, advising companies on drug development from target identification through market approval. Before joining Sofinnova in 2020, he was SVP and Chief Medical Officer of Ascendis Pharma, EVP of Research and Development at InterMune (where he led development and US approval of Esbriet for idiopathic pulmonary fibrosis), and held CMO roles at KaloBios Pharmaceuticals and Halozyme Therapeutics, plus positions at Roche, Amgen, and Merck. He holds a B.A. in Chemistry and an M.D. from the University of Pennsylvania, and completed training in Internal Medicine and Pulmonary and Critical Care Medicine at the University of Colorado, Denver.
- Where does Jonathan Leff work?
- Jonathan Leff is Executive Partner, Private Equity at Sofinnova Ventures and Board director at Axonis Therapeutics and Board director at Adaptive Phage Therapeutics.
- What does Jonathan Leff invest in?
- Jonathan Leff invests in Biotech.
- What check size does Jonathan Leff write?
- Jonathan Leff typically writes checks of $100K – $5M.
- What boards does Jonathan Leff sit on?
- Jonathan Leff holds tracked board seats at Adaptive Phage Therapeutics, Aerovate Therapeutics, Inc., Axonis, Expedition, Genoa Pharmaceuticals, NorthSea.
- Where did Jonathan Leff go to school?
- Jonathan Leff studied at University of Colorado Anschutz (Pulmonary/Critical Care Fellowship); University of Colorado Anschutz (Internal Medicine Internship/Residency); University of Pennsylvania School of Medicine (M.D., Medicine).
Same school
Also attended University of Colorado Anschutz3
Also attended University of Pennsylvania School of Medicine29
René KuijtenInvestor at LSP (Life Sciences Partners)Jun JeonInvestor at Khosla VenturesRené R. KuijtenInvestor at LSP (Life Sciences Partners)Seth GlickmanDigital Health Advisor at Excelerate Health VenturesAaron NelsonPartner at Novo HoldingsFrederick JonesAdvisory Partner at BioAdvance
+ 23 more
Also attended University of Pennsylvania824
Brian ActonCo-founder of WhatsApp; co-founder of Signal FoundationKunal BahlCo-founder of Snapdeal; co-founder of Titan CapitalDasha MaggioPartner at Felicis Ventures, writer on venture capital and founder psychologyNancy WangInvestor at Felicis VenturesLeah von SiemensPartner at Manta Ray VenturesEghosa OmoiguiFounder and Managing General Partner at EchoVC Partners
+ 818 more
Shared employers
Also worked at Axonis Therapeutics2
Also worked at InterMune3
Also worked at Roche95
Joe HorsmanInvestor at Madrona Venture GroupMarco PrunottoInvestor at MedicxiMike FitzgeraldInvestor at High AlphaUri LopatinInvestor at Khosla VenturesJan-Olivier FillolsSenior Managing Director at Marlin Equity PartnersNarges BaniasadiVenture Partner at Think+ Ventures Management, Llc
+ 89 more
Also worked at Amgen65
Parker ConradCo-founder & CEO of RipplingSeth LieblichInvestment Team at 8VCSean BruichChief Technology Officer at Flare Capital PartnersSteph ScottVice President at Questa CapitalBeth SeidenbergFounding Managing Director at Westlake Village BioPartnersKelli McKeirnanDirector of Administration at Westlake Village BioPartners
+ 59 more